New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. The love you have for your dog is hard to beat ...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Corvus Pharmaceuticals Inc. (CRVS) on Tuesday reported a loss of $12.1 million in its fourth quarter. The Burlingame, California-based ...

Some older professionals have taken blue-collar jobs in response to a white-collar hiring slowdown. Blue-collar roles are helping some people make ends meet while they continue their job searches.

Insiders who purchased Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shares in the past 12 months are unlikely to be deeply impacted by the stock's 16% decline over the past week. After taking the ...

Tick collars protect dogs from nasty eight-legged, disease-carrying ticks and may also repel or kill other bothersome critters like fleas and lice. These collars can protect your dog from tick ...

Research and Development Expenses (Q4 2024): $6 million, up from $4 million in Q4 2023. Research and Development Expenses (Full-Year 2024): $19.4 million, up from $16.5 million in 2023. Net Loss ...

CEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% objective response rate ...

(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients ...

"We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "Our Phase 1 ...

Rajeev Dhir is a writer with 10+ years of experience as a journalist with a background in broadcast, print, and digital newsrooms. Amy Soricelli has over 40 years working with job candidates and ...